Skip to content

Trial Summary

A Single-arm, Open-label, Global, Multicenter, Phase 2 Study to Evaluate the Efficacy of AK104 in Patients with Recurrent or Metastatic Cervical Cancer

Acronym:

AK104-201

ACTRN/NCT /ethics:

NCT04380805

Scientific title:

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Sponsor / Cooperative group:

Akeso

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase II
Age Range18+ years
SexFemale
Tumour Stream Cervical
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-07-15
Anticipated End Date2022-02-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Meena Okera
Recruitment StatusRecruiting